Armstrong Advisory Group Inc. Increases Stock Holdings in Boston Scientific Corporation $BSX

Key Points

• Armstrong Advisory Group Inc. increased its stake in Boston Scientific Corporation by 119.1% during the second quarter, now holding shares worth $960,000.
• Several large investors have recently acquired positions in Boston Scientific, contributing to institutional investors owning 89.07% of the company's stock.
• Boston Scientific's latest quarterly earnings report showed a 22.8% year-over-year revenue increase, with earnings per share of $0.75, exceeding estimates.

Armstrong Advisory Group Inc. increased its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 119.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,935 shares of the medical equipment provider's stock after acquiring an additional 4,857 shares during the period. Armstrong Advisory Group Inc.'s holdings in Boston Scientific were worth $960,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in BSX. 1248 Management LLC acquired a new stake in Boston Scientific in the 1st quarter valued at $26,000. Y.D. More Investments Ltd bought a new position in shares of Boston Scientific during the first quarter valued at approximately $27,000. Ameriflex Group Inc. bought a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $31,000. Fourth Dimension Wealth LLC bought a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $36,000. Finally, Oliver Lagore Vanvalin Investment Group bought a new stake in Boston Scientific during the second quarter worth approximately $37,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Down 0.9%

Boston Scientific stock traded down $0.92 during mid-day trading on Monday, reaching $96.91. The stock had a trading volume of 11,012,552 shares, compared to its average volume of 8,405,870. Boston Scientific Corporation has a one year low of $80.64 and a one year high of $109.50. The company has a 50-day moving average price of $104.25 and a two-hundred day moving average price of $102.08. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company has a market capitalization of $143.60 billion, a price-to-earnings ratio of 57.69, a PEG ratio of 2.36 and a beta of 0.65.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the prior year, the firm earned $0.62 EPS. The business's revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on BSX. UBS Group lifted their price objective on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Truist Financial boosted their price target on shares of Boston Scientific from $120.00 to $125.00 and gave the company a "buy" rating in a research report on Thursday, July 24th. Jefferies Financial Group reiterated a "hold" rating on shares of Boston Scientific in a research report on Monday, July 21st. Robert W. Baird increased their target price on shares of Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. Finally, Oppenheimer raised shares of Boston Scientific from a "market perform" rating to an "outperform" rating and raised their target price for the company from $118.00 to $125.00 in a research report on Monday, September 8th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, Boston Scientific has an average rating of "Buy" and an average price target of $118.04.

Insider Activity

In related news, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of the company's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock worth $18,397,457 in the last quarter. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.